What top creators are saying about SPDR S&P Biotech ETF(XBI)

The speaker added to and continued to hold the ETF, preferring sector exposure over selecting individual biotech companies.

The host identified XBI as a healthcare ETF he held or favored and said healthcare funds had been among the stronger recent performers. He was not adding because the fund had not reached his preferred buying level.

A bounce was possible, while a break below the key support after a lower high would make the trend more concerning.

The host said he owned the ETF and was long-term constructive, but provided no specific levels in this discussion.

XBI was included in a speaker's hypothetical portfolio example focused on biotech and AI drug discovery. The 5x goal applied to the combined allocation and was not a forecast or guarantee.

A host cited XBI as a way to invest in biotechnology and AI-assisted drug discovery, expecting biotech companies to be higher in five years. The 5x goal was personal, not a forecast.

Offers diversified exposure to the biotechnology growth cycle that can perform independently of broader tech and crypto markets.

Core thematic allocation positioned for secular growth over a 6-month horizon as macro liquidity conditions evolve.

Identified as a sector AI will disrupt or enhance through accelerated research.

Recommended as a stable core holding to capture AI-driven industry re-rating with lower risk.

Preferred for broader industry exposure to AI-driven drug discovery with better risk/reward.

Emerging as a major beneficiary of applied AI, which is accelerating drug discovery and collapsing medicine costs. The ETF is trending higher and outperforming the Nasdaq 100.

Suggested as a potential investment to gain exposure to the biotechnology sector, which is a key focus of the U.S. government's 'Genesis Mission' AI initiative, a massive potential catalyst for the sector.

The ETF is described as making a 'bearish to bullish reversal' with 'a lot of space to the upside,' driven by increased M&A activity and more attractive valuations in the biotech space.

The biotech index (XBI) is starting to climb back above the $100 mark, and its recovery suggests that institutional investors may be regaining confidence, which could signal a broader turnaround.

The ETF's chart is used as evidence that the biotech sector has been 'dead' for 15 years, making broad, passive investment in the sector a poor strategy.